A screening study on the detection strain of Coxsackievirus A6: the key to evaluating neutralizing antibodies in vaccines

References

• Repass GL, Palmer WC, Stancamplano FF. Hand, foot, and mouth disease: identifying and managing an acute viral syndrome. Cleve Clin J Med. 2014;81(9):537–543. doi: 10.3949/ccjm.81a.13132
   PubMed Web of Science ®Google Scholar
• Mirand A, Cohen R, Bisseux M, et al. A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 2021;26(43):2100978. doi: 10.2807/1560-7917.ES.2021.26.43.2100978
   PubMedGoogle Scholar
• Carmona RCC, Machado BC, Reis FC, et al. Hand, foot, and mouth disease outbreak by Coxsackievirus A6 during COVID-19 pandemic in 2021, São Paulo, Brazil. J Clin Virol. 2022;154:105245. doi: 10.1016/j.jcv.2022.105245
   PubMed Web of Science ®Google Scholar
• Kanbayashi D, Kaida A, Hirai Y, et al. An epidemic of hand, foot, and mouth disease caused by coxsackievirus A6 in Osaka city, Japan, in 2017. Jpn J Infect Dis. 2019;72(5):334–336. doi:10.7883/yoken.JJID.2018.532
   PubMed Web of Science ®Google Scholar
• Lee MHP, Chong YM, Tay CG, et al. Detection of enteroviruses during a 2018 hand, foot and mouth disease outbreak in Malaysia. Trop Biomed. 2021;38(1):150–153. doi: 10.47665/tb.38.1.026
   PubMed Web of Science ®Google Scholar
• Nhan LNT, Khanh TH, Hong NTT, et al. Clinical, etiological and epidemiological investigations of hand, foot and mouth disease in southern Vietnam during 2015 – 2018. PLoSNegl Trop Dis. 2020;14(8):e0008544. doi: 10.1371/journal.pntd.0008544
   PubMed Web of Science ®Google Scholar
• Xu SS, Li HJ, Qiao P, et al. Neonatal hand, foot, and mouth disease due to coxsackievirus A6 in Shanghai. BMC Pediatr. 2020;20(1):364. doi: 10.1186/s12887-020-02262-y
   PubMed Web of Science ®Google Scholar
• Fonseca MC, Sarmiento L, Resik S, et al. Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011-2013. Arch Virol. 2014;159(9):2451–2455. doi: 10.1007/s00705-014-2071-x
   PubMed Web of Science ®Google Scholar
• Puenpa J, Chieochansin T, Linsuwanon P, et al. Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012, Thailand, 2013. Emerg Infect Dis. 2013;19(4):641–643. doi: 10.3201/eid1904.121666
   PubMed Web of Science ®Google Scholar
• Mirand A, Henquell C, Archimbaud C, et al. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clin Microbiol Infect. 2012;18(5):E110–E118. doi: 10.1111/j.1469-0691.2012.03789.x
   PubMed Web of Science ®Google Scholar
• Sinclair C, Gaunt E, Simmonds P, et al. Atypical hand, foot, and mouth disease associated with coxsackievirus A6 infection, Edinburgh, United Kingdom, January to February 2014. Euro Surveill. 2014;19(12):20745. doi: 10.2807/1560-7917.es2014.19.12.20745
   PubMedGoogle Scholar
• Horsten HH, Kemp M, Fischer TK, et al. Atypical Hand, Foot, and mouth disease caused by coxsackievirus A6 in Denmark: A diagnostic mimicker. Acta DermVenereol. 2018;98(3):350–354. doi: 10.2340/00015555-2853
   PubMed Web of Science ®Google Scholar
• Cisterna DM, Lema CL, Martinez LM, et al. Atypical hand, foot, and mouth disease caused by Coxsackievirus A6 in Argentina in 2015. Rev Argent Microbiol. 2019;51(2):140–143. doi: 10.1016/j.ram.2018.05.003
   PubMed Web of Science ®Google Scholar
• Neri I, Dondi A, Wollenberg A, et al. Atypical forms of hand, foot, and mouth disease: A prospective study of 47 Italian children. Pediatr Dermatol. 2016;33(4):429–437. doi: 10.1111/pde.12871
   PubMed Web of Science ®Google Scholar
• Justino MCA, Mesquita DS, Souza MF, et al. Atypical hand-foot-mouth disease in Belém, Amazon region, northern Brazil, with detection of coxsackievirus A6. J Clin Virol. 2020;126:104307. doi: 10.1016/j.jcv.2020.104307
   PubMed Web of Science ®Google Scholar
• Hayman R, Shepherd M, Tarring C, et al. Outbreak of variant hand-foot-and-mouth disease caused by coxsackievirus A6 in Auckland, New Zealand. Paediatr Child Health. Paediatr Child Health. 2014;50(10):751–755. doi: 10.1111/jpc.12708
   PubMed Web of Science ®Google Scholar
• Li YN, Xiong TT, Meng Y, et al. Risk factors for severe hand, foot, and mouth disease infected with Coxsackievirus A6: A hospital-based case-control study. J Med Virol. 2020;3144–3150. doi: 10.1002/jmv.26343
   PubMed Web of Science ®Google Scholar
• Du ZQ, Zhao YL, Luo YJ, et al. Ongoing change of severe hand, foot, and mouth disease pathogens in Yunnan, China, 2012 to 2016. J Med Virol. 2019;91(5):881–885. doi: 10.1002/jmv.25393
   PubMed Web of Science ®Google Scholar
• Luchs A, Azevedo LS, Souza EV, et al. Coxsackievirus A6 strains causing an outbreak of hand-foot-and-mouth disease in Northeastern Brazil in 2018. Rev Inst Med Trop Sao Paulo. 2022;64:e16. doi: 10.1590/s1678-9946202264016
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep. 2012;61(12):213–214.
   PubMedGoogle Scholar
• Chetrit EB, Well YW, Shulman LM, et al. Coxsackievirus A6-related hand foot and mouth disease: skin manifestations in a cluster of adult patients. J Clin Virol. 2014;59(3):201–203. doi: 10.1016/j.jcv.2013.12.012
   PubMed Web of Science ®Google Scholar
• Yip CCY, Lau SKP, Woo PCY, et al. Human enterovirus 71 epidemics: what's next?. Emerg Health Threats J. 2013;6:19780. doi: 10.3402/ehtj.v6i0.19780
   PubMedGoogle Scholar
• Chen B, Sumi A, Toyoda S, et al. Time series analysis of reported cases of hand, foot, and mouth disease from 2010 to 2013 in Wuhan, China. BMC Infect Dis. 2015;15:495. doi: 10.1186/s12879-015-1233-0
   PubMed Web of Science ®Google Scholar
• Puenpa J, Saengdao N, Khanarat N, et al. Evolutionary and genetic recombination analyses of coxsackievirus A6 variants associated with hand, foot, and mouth disease outbreaks in Thailand between 2019 and 2022. Viruses. 2023;15(1):73. doi: 10.3390/v15010073
   Web of Science ®Google Scholar
• Yoshitomi H, Ashizuka Y, Ichihara S, et al. Molecular epidemiology of coxsackievirus A6 derived from hand, foot, and mouth disease in Fukuoka between 2013 and 2017. J Med Virol. 2018;90(11):1712–1719. doi: 10.1002/jmv.25250
   PubMed Web of Science ®Google Scholar
• Kanbayashi D, Kaida A, Hirai Y, et al. An epidemic of hand, foot, and mouth disease caused by coxsackievirus A6 in Osaka city, Japan, in 2017. Jpn J Infect Dis. 2019;72(5):334–336. doi: 10.7883/yoken.JJID.2018.532
   PubMed Web of Science ®Google Scholar
• Sanjay RE, Josmi J, Sasidharanpillai S, et al. Molecular epidemiology of enteroviruses associated with hand, foot, and mouth disease in South India from 2015 to 2017. Arch Virol. 2022;167(11):2229–2238. doi: 10.1007/s00705-022-05561-0
   PubMed Web of Science ®Google Scholar
• Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis. 2011;11:346. doi: 10.1186/1471-2334-11-346
   PubMed Web of Science ®Google Scholar
• Dong SB, Wang XL, Huo D, et al. Epidemiological characteristics of hand, foot and mouth disease among people aged 6 and over in Beijing, 2011-2020. Zhonghua Liu Xing Bing Xue Za Zhi. 2022;43(2):207–212. doi: 10.3760/cma.j.cn112338-20210511-00387
   PubMedGoogle Scholar
• Wang JY, Teng Z, Cui XQ, et al. Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012–2016, People’s Republic of China, 2018. Emerg Microbes Infect. 2018;7(1):1. doi: 10.1038/s41426-017-0011-z
   PubMedGoogle Scholar
• Lu J, Zeng H, Zheng H, et al. Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic. Clin Microbiol Infect. 2014;20(7):O442–O445. doi: 10.1111/1469-0691.12468
   Google Scholar
• Li JL, Yuan J, Yang F, et al. Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. J Infect. 2014;69(3):299–303. doi: 10.1016/j.jinf.2014.04.001
   PubMed Web of Science ®Google Scholar
• Gu HY, Ma CJ, Yang QZ, et al. Hand, foot and mouth disease caused By coxsackievirus A6, Beijing, 2013. Pediatr Infect Dis J. 2014;33(12):1302–1303. doi: 10.1097/INF.0000000000000467
   PubMed Web of Science ®Google Scholar
• Tan XJ, Li L, Zhang BM, et al. Molecular epidemiology of coxsackievirus A6 associated with outbreaks of hand, foot, and mouth disease in Tianjin, China, in 2013. Arch Virol. 2015;160(4):1097–1104. doi: 10.1007/s00705-015-2340-3
   PubMed Web of Science ®Google Scholar
• Han JF, Xu S, Zhang Y, et al. Hand, foot and mouth disease outbreak caused by coxsackievirus A6, China 2013. J Infect. 2014;69(3):303–305. doi: 10.1016/j.jinf.2014.03.015
   PubMed Web of Science ®Google Scholar
• Li JJ, Pan H, Wang XS, et al. Epidemiological surveillance of hand, foot and mouth disease in Shanghai in 2014-2016, prior to the introduction of the enterovirus 71 vaccine. Emerg Microbes Infect. 2018;7(1):1–7. doi: 10.1038/s41426-018-0035-z
   PubMedGoogle Scholar
• Cui Y, Yang YN, Zheng RR, et al. Epidemiological characteristics of hand, foot, and mouth disease clusters during 2016-2020 in Beijing, China. J Med Virol. 2022;94(10):4934–4943. doi: 10.1002/jmv.27906
   PubMed Web of Science ®Google Scholar
• Duan XX, Zhang CY, Wang X, et al. Molecular epidemiology and clinical features of hand, foot and mouth disease requiring hospitalization after the use of enterovirus A71 inactivated vaccine in Chengdu, People’s Republic of China, 2017-2022: a descriptive study. Emerg Microbes Infect. 2022;11(1):2510–2519. doi: 10.1080/22221751.2022.2125346
   PubMed Web of Science ®Google Scholar
• Cabrerizo M, Tarragó D, Almagro CM, et al. Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain. Clin Microbiol Infect. 2014;20(3):O150–O156. doi: 10.1111/1469-0691.12361
   PubMed Web of Science ®Google Scholar
• Andrés C, Guasch E, Piñana M, et al. Recombinant CV-A6 strains related to hand-foot-mouth disease and herpangina at primary care centers (Barcelona, Spain). Future Microbiol. 2019;14:499–507. doi: 10.2217/fmb-2018-0336
   PubMed Web of Science ®Google Scholar
• Bujaki E, Farkas A, Rigó Z, et al. Distribution of enterovirus genotypes detected in clinical samples in Hungary, 2010-2018. Acta Microbiol Immunol Hung. 2020;67(4):201–208. doi: 10.1556/030.2020.01200
   PubMed Web of Science ®Google Scholar
• Han Y, Ji H, Shen WQ, et al. Disease burden in patients with severe hand, foot, and mouth disease in Jiangsu Province: a cross-sectional study. Hum Vaccin Immunother. 2022;18(5):2049168. doi: 10.1080/21645515.2022.2049168
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang YP, Bian LL, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606. doi: 10.1586/14760584.2016.1138862
   PubMed Web of Science ®Google Scholar
• Mao QY, Wang YP, Bian LL, et al. EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect. 2016;5(7):1. doi: 10.1038/emi.2016.73
   Google Scholar
• Zhou Y, Shen CY, Zhang C, et al. Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res. 2016;132:165–169. doi: 10.1016/j.antiviral.2016.06.004
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Dong ZP, Wang Q, et al. Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine. 2018;36(46):7095–7104. doi: 10.1016/j.vaccine.2018.09.069
   PubMed Web of Science ®Google Scholar
• Caine EA, Fuchs J, Das SC, et al. Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses. 2015;7:5919–5932. doi: 10.3390/v7112916
   PubMed Web of Science ®Google Scholar
• Liu CC, Guo MS, Rung S, et al. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Res. 2016:129:58–66. doi: 10.1016/j.antiviral.2016.02.008
   PubMed Web of Science ®Google Scholar
• Lim H, Ln HJ, Lee JA, et al. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine. 2018;36(24):3445–3452. doi: 10.1016/j.vaccine.2018.05.005
   PubMed Web of Science ®Google Scholar
• Zhang W, Dai WL, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7(1):1. doi: 10.1038/s41426-018-0094-1
   PubMedGoogle Scholar
• Liu P, Yuan YD, Cui BP, et al. Cross-Antigenicity between EV71 Sub-genotypes: implications for vaccine efficacy. Viruses. 2021;13(5):720. doi: 10.3390/v13050720
   PubMed Web of Science ®Google Scholar
• Zhu WB, Jin PF, Li JX, et al. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints. Expert Review of Vaccines.2017;16(9): 945–949. doi: 10.1080/14760584.2017.1335603
   Google Scholar
• Klein M, Chong P. Is a multivalent hand, foot, and mouth disease vaccine feasible? Hum Vaccin Immunother. 2015;11(11):2688–2704. doi: 10.1080/21645515.2015.1049780
   PubMed Web of Science ®Google Scholar
• Li Y, Gao F, Wang YM, et al. Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial. Lancet Reg Health West Pac. 2021;16:100284. doi: 10.1016/j.lanwpc.2021.100284
   PubMedGoogle Scholar
• Zhu FC, Xu WB, Xia JL, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923
   PubMed Web of Science ®Google Scholar
• Huo YQ, Yang JH, Liu P, et al. Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains. Hum Vaccin Immunother. 2024;17(12):5334–5347. doi: 10.1080/21645515.2021.1978792
   Google Scholar
• Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5(2):85–86. doi: 10.5501/wjv.v5.i2.85
   PubMedGoogle Scholar
• Song Y, Zhang Y, Ji TJ, et al. Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci Rep. 2017;7(1):5491. doi: 10.1038/s41598-017-05618-0
   PubMedGoogle Scholar
• Zhu PY, Ji WQ, Li D, et al. Current status of hand-foot-and-mouth disease. J Biomed Sci. 2023;30(1):15. doi: 10.1186/s12929-023-00908-4
   PubMed Web of Science ®Google Scholar
• Dalldorf G. The coxsackievirus group. AnnN Y Acad Sci 1953;56(3):583–586. doi: 10.1111/j.1749-6632.1953.tb30251.x
   PubMed Web of Science ®Google Scholar
• Fu XM, Wan ZZ, Li YP, et al. National epidemiology and evolutionary history of four hand, foot and mouth disease-related enteroviruses in China from 2008 to 2016. Virol Sin. 2020;35(1):21–33. doi: 10.1007/s12250-019-00169-2
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhang C, Zhou Y, et al. A 3.0-angstrom resolution cryo-electron microscopy structure and antigenic sites of coxsackievirus A6-like particles. J Virol. 2018;92(2):e01257. doi: 10.1128/JVI.01257-17
   PubMed Web of Science ®Google Scholar
• Zhu R, Yu H, Hong QY, et al. Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nat Commun. 2017;8(1):505. doi: 10.1038/s41467-017-00477-9
   PubMedGoogle Scholar
• World Health Organization. Recommendations to assure the quality, safety and 6 efficacy of Enterovirus 71 vaccines (inactivated).[cited 2023 Oct 10]. Available from: https://www.who.int/news-room/articles-detail/call-for-comments-on-ev71-recommendations.
   Google Scholar
• Lei DL, Griffiths E, Martin J. WHO working group meeting to develop WHO Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines. Vaccine. 2020;38(32):4917–4923. doi: 10.1016/j.vaccine.2020.05.001
   PubMed Web of Science ®Google Scholar
• Mao QY, Li N, Yu X, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol. 2012;157(1):37–41. doi: 10.1007/s00705-011-1136-3
   PubMed Web of Science ®Google Scholar
• Elmgren L, Li XG, Wilson C, et al. A global regulatory science agenda for vaccines. Vaccine. 2013;31(Suppl):B163–B175. doi: 10.1016/j.vaccine.2012.10.117
   PubMedGoogle Scholar